GGrantIndex
Sort

130,381 grants matching hiv

Application of a syndemic framework to HPV and HSV infection in emergent adult men

$787,932
Danielle C Ompad · New York University · R01 · FY2017 · AI

Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling

$787,916
George Louis Drusano · Ordway Research Institute, Inc. · R01 · FY2008 · AI

(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years

$787,905
Joel Palefsky · University Of California, San Francisco · R01 · FY2016 · CA

Trial of Metformin for TB/HIV Host-directed Therapy

$787,888
Hardy Kornfeld · Univ Of Massachusetts Med Sch Worcester · U01 · FY2020 · AI

Alcohol Use Disorder Treatment Simulation: Modeling treatment impacts on alcohol-related disparities

$787,885
Katherine J. Karriker-Jaffe · Research Triangle Institute · R01 · FY2023 · AA

Indiana HIV Surveillance System

$787,855
Larry A Harris · Indiana State Department Of Health · U62 · FY2013 · PS

Determination of mucosal immune responses to, and infection of the gastrointestinal tract by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

$787,826
Saurabh Mehandru · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · DK

Screen Smart: Using Digital Health to Improve HIV Screening and Prevention for Adolescents in the Emergency Department

$787,787
Jennifer Lynn Reed · Cincinnati Childrens Hosp Med Ctr · R01 · FY2024 · HD

Novel DFG out inhibitors of Abl-kinases to treat PML

$787,776
Milton H. Werner · Inhibikase Therapeutics · R44 · FY2016 · AI

ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1

$787,723
Scripps Research Institute · R01 · FY2005 · AI

Following a U.S. National Cohort of Vulnerable Men to Improve HIV Prevention and Care

$787,695
Christian Grov · Graduate School Of Public Health And Health Policy · UH3 · FY2021 · AI

Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease

$787,681
Michael Ilya Bukrinsky · George Washington University · R01 · FY2018 · HL

Targeted interventions to reduce or eliminate the SIV reservoir in a novel model of elite control

$787,676
James A Hoxie · University Of Pennsylvania · R01 · FY2023 · AI

HEALTH RELATED INTERVENTIONS FOR PERSONS LIVING WITH HIV

$787,621
University Of California San Francisco · U10 · FY2001 · MH

PS10-1085 HIV PREV/MOST-AT-RISK POP.(MARPS), REPUBLIC OF MOZAMBIQUE, UNDE

$787,521
Martha Scherzer · Global Health Communications, Llc · U2G · FY2014 · PS

Comparative Study of Molecular Signatures in HIV-Related Neuropathogenesis and Alzheimer's Disease

$787,498
Michelli Faria De Oliveira · University Of California, San Diego · R01 · FY2020 · AG

Establishing a Brain Health Index

$787,477
Michael Brandon Westover · Beth Israel Deaconess Medical Center · R01 · FY2024 · NS

Eradication of latent SIV from the CNS

$787,475
Andrew G Maclean · Tulane University Of Louisiana · R01 · FY2018 · NS

Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis

$787,467
Bjoern Markus Reinhard · Boston University (Charles River Campus) · R01 · FY2023 · AI

ERC Einstein Rockefeller CUNY Center for AIDS Research

$787,440
Kathryn M Anastos · Albert Einstein College Of Medicine · P30 · FY2023 · AI

Leveraging data to identify opportunities to address insecure care connections and poor health outcomes among people living with HIV

$787,410
Sarah Elizabeth Wiehe · Indiana University Indianapolis · R01 · FY2020 · HD

Cannabinoid modulation of EV composition and function in HIV/SIV infection

$787,400
Chioma M Okeoma · State University New York Stony Brook · R01 · FY2020 · DA

Development of a Self Inactivating, Highly Effective TB Vaccine

$787,367
Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI

Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study

$787,348
Martin F Shapiro · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · DK

AIBP and regulation of neuropathic pain

$787,291
Yury Miller · University Of California, San Diego · R01 · FY2019 · NS